In particular, in terms of platinum‐based chemotherapy, our previous study showed that patients with IDH1 mutant CCA did not have improved outcomes with second‐line FOLFOX/CAPOX compared to patients with IDH1 wild type CCA [37]. The gene discussed is IDH1; the disease is cholangiocarcinoma.